None listed
Conditions
Interventions
None listed
Sponsors
Korea University Anam Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Males and females over 19 years old 2) Patients diagnosed with NVAF 3) Patients with CHA2DS2-VASc score of 1 (2 for females) * CHA2DS2-VASc score: Assess the risk of stroke up to 9 points by considering the following factors: Congestive heart failure (+1 point), Hypertension (+1 point), Age 75 or over (+2 points), Diabetes mellitus (+1 point), Stroke (+2 points), Transient Ischemic Attack (TIA)/Thromboembolism (TE), Vascular disease (+1 point each), Age 65-74 (+1 point), and Sex (+1 point for females).[6] 4) When the investigator determines that the use of an anticoagulant is necessary to prevent stroke or systemic embolism 5) Patients who have no history of taking medications containing Apixaban within 6 months of screening 6) When the patients who understand the description of this study, agree to participate in the study, and completed/submitted the informed consent form
Exclusion criteria
Exclusion criteria: 1) Patients who are contraindicated according to the precautions for using Apixaban 2) Pregnant and lactating women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incident rate of stroke or systemic embolism;Incident rate of major bleeding events | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence rate of all major bleeding events by each organ;Overall incidence rate and incidence rate by each organ of all bleeding events excluding major bleeding events according to ISTH criteria;All bleeding events according to the HAS-BLED risk score and the number of subjects and incidence rate of major bleeding events;Assessment of Apixaban use pattern (Totoal prescription period and compliance of Apixaban, Change rates of Apixaban dosage and its reasons, Discontinuation rates of Apixaban and its reasons);Incidence rate of final clinical events (Mortality, Transient Ischaemic Attack, Myocardial Infarction, Exacerbation of heart failure);Other adverse events | — |
Countries
Korea, Republic of
Contacts
Public ContactYun-Gi Kim
Korea University Anam Hospital
Outcome results
None listed